ACME UNITED CORP - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. ACME United Corp is a manufacturer and marketer of first aid, medical, cutting, and sharpening products. The company operates in three reportable segments: United States, Canada, and Europe. A significant event during the period was the acquisition of "My Medic" assets on January 15, 2026, expanding the company's tactical and emergency response product lines.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $52.3 million | $46.0 million |
| Gross Profit | $20.8 million (39.7% margin) | $17.9 million (39.0% margin) |
| Operating Income | $1.7 million | $2.4 million |
| Net Income | $0.99 million | $1.65 million |
| Diluted EPS | $0.24 | $0.41 |
| Cash and Equivalents | $4.2 million | $3.4 million |
| Long-Term Debt | $33.0 million | $11.9 million |
| Working Capital | $82.5 million | $73.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% year-over-year. Excluding the My Medic acquisition, comparable sales grew 6%. The U.S. segment grew 12%, Canada 16%, and Europe 32% (driven by e-commerce and a prior acquisition).
- Profitability Decline: Despite revenue growth, operating income fell 28% to $1.7 million. This was primarily due to higher SG&A expenses (up 23%) and increased cost of sales driven by tariff-related costs and quality assurance investments at the Med-Nap facility.
- Debt Increase: Long-term debt increased by approximately $21.2 million to $33.0 million, largely to fund the My Medic acquisition and working capital needs.
- Acquisition Impact: The My Medic acquisition contributed $3.4 million in revenue in Q1 2026. The purchase price was $18.6 million, with $14.4 million paid in cash at closing.
Outlook, Risks, and Management Commentary
- Tariff Mitigation: Management notes that high tariff expenses recognized in Q1 were due to selling inventory subject to 2025 rates. They expect the impact to lessen in the remainder of 2026 as inventory subject to lower tariffs (set in Nov 2025 and Feb 2026) is sold.
- Supply Chain Strategy: The company has commenced purchasing approximately $10 million of inventory for delivery in Q2 and Q3 2026 to mitigate potential shortages or price increases resulting from geopolitical conflicts (specifically citing the war in Iran).
- Liquidity: The company maintains a $65 million revolving credit facility with $32.0 million available as of March 31, 2026. Management believes cash flow and available credit are sufficient for the next 12 months.
- Risks: Key risks include global trade policies, tariffs on Chinese goods, geopolitical instability in the Middle East and Ukraine, inflation, and supply chain disruptions.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress of My Medic and whether the $1.0 million contingent payment milestone is achievable.
- Tariff Exposure: Confirm the timeline for selling off high-tariff inventory and the effectiveness of supply chain diversification efforts.
- Debt Covenants: Monitor compliance with the funded debt to EBITDA and fixed charge coverage ratios under the HSBC revolving loan agreement.
- Margin Pressure: Assess if SG&A expenses will normalize or if tariff-related costs will persist in future quarters.
- Inventory Levels: Review inventory turnover (currently 2.0) to ensure the $10 million pre-purchase strategy does not lead to excess stock.